Idarubicin combined chemotherapy regimen for 22 cases with refractory or relapsed multiple myeloma
- VernacularTitle:去甲氧柔红霉素联合方案治疗22例难治性、复发性多发性骨髓瘤
- Author:
Waiyi ZOU
;
Shaokai LUO
;
Juan LI
- Publication Type:Journal Article
- Keywords:
multiple myeloma;
chemotherapy;
idarubicin
- From:China Oncology
1998;0(01):-
- CountryChina
- Language:Chinese
-
Abstract:
Purpose:To study the efficacy and toxicity of VIDM regimen (vincristine,idarubicin,dexamethasone and melphalan) for refractory or relapsed multiple myeloma(MM).Methods:45 refractory or relapsed MM patients were randomized into two groups: VIDM group(treatment group) had 22 patients treated with VIDM regimen, VAD group(control group) had 23 patients with VAD regimen.Results:The effective rate with VIDM regimen (59.1%) was significantly higher than that of VAD regimen (26.1%) (P
